White House Plans Temporary Access to Six Peptides: What It Means for Providers and Telehealth

As of October 10, 2026: This article discusses a reported proposal, not an announced or effective FDA policy. Advisory committee recommendations are not FDA approval or authorization to compound. General educational information only—not legal or medical advice. Confirm current requirements with FDA, applicable state boards, qualified counsel, and your licensed clinicians.

On October 7, 2026, The Washington Post reported that the Trump administration is working on a stopgap that would allow certain previously restricted peptides to be sold temporarily while the FDA writes the actual rules for them. If you run a longevity, wellness, weight loss, or telehealth practice, you have probably already heard from a patient, a pharmacy rep, or a marketing partner that peptides are "coming back."

The short answer is that a temporary pathway would be a real shift in how these peptides can be compounded and prescribed, but it would not be FDA approval, it would not be permanent, and it will almost certainly come with conditions that most practices are not set up to meet today. Below is what was reported, how we got here, and what it means if you are in this industry.

What the Washington Post reported

According to two people familiar with the plans, the administration is preparing a temporary policy that would let some compounding pharmacies dispense certain peptides that had previously been restricted, while federal health officials work out formal regulations. The plan has not been announced, its timing is unclear, it could still change, and the reporting did not say which peptides would be included. The sources said officials are looking for guardrails around the policy, and HHS did not comment (Becker's Hospital Review).

The mechanism being discussed is what the FDA calls interim enforcement discretion, which is the agency essentially saying it will spend its enforcement resources elsewhere. The Alliance for Pharmacy Compounding told the Post it has been asking FDA to use that approach so state-licensed compounding pharmacies can prepare these drugs for patients who have a prescription. The American Academy of Peptide Medicine has pushed for the same thing, arguing it would pull patients away from the gray and black market (Washington Post via Anchorage Daily News).

One detail worth noticing: this is happening while FDA moves in the opposite direction on compounded GLP-1s, which are also peptides. The reported proposal would ease enforcement for one group of peptides while FDA tightens enforcement on another. It should not be read as a general opening of the door.

How we got here

This did not start last week. It is the latest step in a three-year back and forth over whether compounding pharmacies can make these peptides at all.

The six peptides PCAC recommended, each in free base and acetate forms, are below (McDermott Will & Schulte):

• BPC-157
• TB-500
• KPV
• MOTS-c
• Epitalon
• Semax

The seventh, Emideltide (DSIP), was not recommended, on a 6 to 7 vote with one abstention. These are the six peptides recommended by the advisory committee—not a confirmed list for the reported temporary policy. The reporting did not identify which substances a final policy would cover.

One thing that got lost in the April headlines: coming off Category 2 did not make these peptides legal to compound. Removal from Category 2 does not, by itself, authorize compounding or put a substance under FDA's interim enforcement policy, and FDA never moved these peptides into Category 1 (JD Supra). That gap is exactly what the stopgap is meant to fill.

What enforcement discretion is and what it is not

Enforcement discretion does not change the law. It is FDA saying it does not intend to take action against pharmacies for compounding a substance that has not been formally added to the bulks list yet, as long as they meet whatever conditions FDA attaches. FDA has used this kind of bridge for years through its Category 1 interim policy, precisely because adding a substance to the bulks list takes so long (Buchanan Ingersoll & Rooney).

The permanent path is notice-and-comment rulemaking: FDA issues a proposed rule, takes comments, reviews the record, and then publishes a final rule. There is no deadline for any of it. The last comparable example took more than two years, with a proposed rule in December 2016 and a final rule in February 2019 (Buchanan Ingersoll & Rooney). A second PCAC meeting on additional peptides is also expected before the end of February 2027 (Orrick).

I said after the July vote that this would not be a quick rollout, because FDA has to write the policy and build the monitoring and oversight around it before anything really changes. The stopgap does not contradict that, it confirms it. The administration is reaching for a temporary tool because the permanent process is slow, and that should tell you how to treat whatever comes out of it.

The practical difference between "enforcement discretion" and "approved" comes down to a few things:

• It is not approval. None of these peptides would be FDA-approved drugs, and none would have gone through the clinical trials an approved drug goes through.
• It can be withdrawn. A policy like this can be narrowed or pulled by the agency without a rulemaking process, whether because of a safety signal, a court challenge, or a change in leadership.
• It is conditional. The "guardrails" in the reporting are the conditions, and if a pharmacy or prescriber falls outside them, the discretion does not cover them.

If you lived through compounded semaglutide and tirzepatide, you already know how this ends when the window closes. Those products were compounded at scale under shortage rules, and once FDA declared the shortages resolved, compounders and the telehealth companies built on them had a short wind-down period to stop. Temporary means temporary, and the practices that did well were the ones that had a plan for the day it changed.

What it means for practices, telehealth companies, and prescribers

The pharmacy channel opens, the gray market does not. The pathway being discussed concerns state-licensed 503A pharmacies filling patient-specific prescriptions; the scope of any actual policy must be confirmed in FDA’s published text. The bulk ingredient still has to come from an FDA-registered manufacturer with a certificate of analysis (FDA Law Blog). "Research use only" vials ordered online do not become compliant because a pharmacy down the street can now make the same peptide. FDA has also said nothing about 503B outsourcing facilities for these peptides, so do not assume office-use stock is coming with it.

Marketing is where most companies will get caught. None of these peptides are FDA-approved, and nothing about a temporary policy changes that, so "FDA approved" or "FDA cleared" language is off the table. The advertising rules will stay tight even if compounding opens up, and FDA sent warning letters to 30 telehealth companies in March 2026 alone (FDA Law Blog). Expect a wave of peptide marketing the week a policy is announced, and expect regulators to be watching that wave.

Prescribers carry the clinical risk. FDA's own scientists found little data on effectiveness for the proposed uses and recommended against all seven peptides (AP via KSTP). That record does not go away when enforcement eases. If a patient has a bad outcome, the question will be whether your protocol, your informed consent, and your documentation reflected what the evidence actually shows. This is the same pattern I see across DTC telehealth: when there is no rule written specifically for what you are doing, regulators and plaintiffs lean on existing standards and adjacent authority instead.

State law still applies. Federal enforcement discretion does not override state boards of pharmacy or medical boards, and states can be stricter than FDA. A national telehealth program needs a state-by-state view of who can prescribe, which pharmacies can ship where, and what each board expects in the chart.

The guardrails are still unknown. The reporting said officials want guardrails but did not say what they are. Based on what FDA flagged and what industry has proposed, it is reasonable to expect some mix of testing and sourcing standards, labeling, physician oversight, and adverse event reporting (Buchanan Ingersoll & Rooney). Practices that already operate that way will be able to move quickly. Practices that do not will spend the window catching up.

The policy is political, so it can move. This direction is being driven by HHS leadership over the objections of FDA career scientists, and the advisory panel's makeup has already drawn conflict of interest questions. That does not mean it will be reversed, but it does mean you should not build a business that only works if this specific policy lasts forever.

What is the risk, and does a stopgap lower it?

The question I get most is "what risk am I taking on?" and the honest answer is that it depends on where you sit in the supply chain, because the law puts different obligations on the pharmacy, the seller, the prescriber, and the company doing the marketing. A temporary pathway would lower risk meaningfully for one lane, licensed pharmacies compounding the named peptides for patients with prescriptions under FDA's conditions, and change very little for everyone operating outside that lane.

Where things stand today

A 503A pharmacy can compound from a bulk ingredient only if it is part of a USP monograph, a component of an FDA-approved drug, or on the 503A bulks list. These six peptides are none of those, and FDA has not placed them in Category 1, so compounding them today falls outside the protections 503A gives pharmacies, even after the April removal from Category 2 (JD Supra, Buchanan Ingersoll & Rooney). A product compounded outside those protections can be treated as an unapproved new drug, which is the starting point for everything below.

What the warning letters and cases show

Does the government's signal change the picture?

A published policy could change the federal enforcement picture for the pharmacy lane. A news report or government signal alone does not create that protection. If FDA publicly says it will not act against pharmacies compounding these peptides under stated conditions, the practical likelihood of federal action against a compliant pharmacy, and the prescribers using it, drops a lot.

What the signal does not do is make the product approved, bind state regulators, or protect anyone against a patient lawsuit. Enforcement discretion is also a choice the agency makes, not a right it grants. Under long-standing Supreme Court precedent, an agency's decision about whether to enforce is generally left to the agency (Heckler v. Chaney, 1985), which also means nobody can make FDA keep a discretion policy in place once it decides to end it. The risk does not disappear, it concentrates on whoever operates outside the guardrails or keeps going after the window closes.

What to do now

Nothing has been announced yet, so the right move is to get ready rather than launch. If peptides are part of your plan, this is the work to do before a policy drops:

• Do not launch or market off a news report. Wait for FDA's actual policy, read the conditions, and confirm which peptides it covers.
• Look at what you are already offering. If any peptide in your practice is coming from a research supplier or an unverified source, stop and fix that now.
• Vet your pharmacy. Ask where the bulk ingredient comes from, whether it ships with a certificate of analysis, which states the pharmacy is licensed to ship into, and what testing it does.
• Write the protocol before the product. Patient selection, dosing, monitoring, and when to stop should be documented and owned by your medical director, not borrowed from a vendor or an influencer.
• Update informed consent. Patients should understand that the peptide is compounded, not FDA-approved, and supported by limited evidence.
• Review your marketing and website claims. Remove anything that implies approval, cures, or guaranteed results.
• Check your malpractice coverage. Confirm your policy covers prescribing compounded, unapproved products in every state where you see patients.
• Plan for the window closing. Know what you will do for current patients if the policy is narrowed or withdrawn.

How Camino helps

The peptide space has changed direction at least four times since 2023, and it will keep moving as FDA publishes conditions, holds the next PCAC meeting, and decides on rulemaking. The practices that come out of this in good shape are the ones that treat compliance as something they maintain, not something they set up once.

Camino Strategy Group, LLC, a compliance consulting firm, provides guidance and support for telehealth companies, longevity and wellness practices, and independent clinicians offering or planning to offer peptides, including:

• Regulatory tracking: plain-English updates when FDA, HHS, or state boards act, and what each change means for your operations
• Program readiness review: a look at what you offer today, where it is sourced, and where your exposure sits by role
• Clinical infrastructure: compliance documentation support for clinician-owned protocols, medical director oversight, and informed consent; clinical decisions remain with licensed treating clinicians
• Pharmacy and supply chain vetting: questions to ask, documents to collect, and state shipping coverage to confirm
• Marketing and website review: a claim-by-claim review against current FDA and FTC enforcement themes
• Structure and licensing: entity-structure and multi-state licensing coordination, with legal questions referred to qualified counsel

If you are planning a peptide offering, or already have one and want to know where you stand, reach out and we will walk you through it before the policy lands, not after.

References

News and reporting

• The Trump administration is paving way for temporary sale of some unapproved peptides, The Washington Post (via Anchorage Daily News), October 7, 2026
• HHS plans stopgap to allow sales of some unapproved peptides, Becker's Hospital Review, October 2026 FDA panel narrowly backs unapproved peptide drugs, Associated Press via KSTP, July 2026 FDA to weigh easing limits on unproven peptides, Associated Press Court sides with FDA in tirzepatide shortage fight, Becker's Hospital Review Utah physician indicted on drug charges, Becker's ASC Review, April 2026

Government sources

FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s, FDA, March 3, 2026

• Utah licensed osteopathic physician indicted for allegedly receiving misbranded drugs from China, U.S. Attorney's Office, District of Utah, April 2026 Illinois man illegally purchased and sold peptides, U.S. Attorney's Office, Western District of Pennsylvania, 2013 Owner of bodybuilding drug companies admits to selling misbranded drugs, U.S. Attorney's Office, District of Maryland
• Outsourcing Facilities Association v. FDA, No. 25-10600, U.S. Court of Appeals for the Fifth Circuit
• Heckler v. Chaney, 470 U.S. 821 (1985), U.S. Supreme Court

Legal and industry analysis

FDA Advisory Committee Voted Yes on Six Peptides. Now What?, Buchanan Ingersoll & Rooney, August 18, 2026

• Bulk list bound: PCAC backs majority of peptides in two-day public meeting, McDermott Will & Schulte, July 27, 2026 GLP-1 Update: Court Backs FDA in Tirzepatide Compounding Case, McDermott Will & Schulte Compounding Panel Backs Peptides for the 503A Bulks List, Frier Levitt, July 24, 2026 FDA telehealth advertising and compounded GLP-1 compliance, Frier Levitt, March 2026 GLP-1 Compliance: FDA Targets Telehealth Marketing in 30 New Warning Letters, Foley & Lardner, March 2026 Indictment of Osteopathic Physician Signals Shift in Peptide Enforcement, Stevens & Lee FDA Peptide Compounding Vote: What to Watch at the July PCAC Meeting, Orrick, July 21, 2026 FDA's Pep(tide) Rally! Post 1 and Post 2, FDA Law Blog, April 2026 Tiny Chains, Big Changes? What FDA's Latest Actions Mean for Peptide Compounding, JD Supra Navigating the 2026 Peptide Regulatory Landscape, D.J. Holt Law Settlement reached in Evexias suit against FDA, Alliance for Pharmacy Compounding, September 2024

This post is for general information and is not legal advice.